Table 2.
Trial process chart
| Period | Screening | Treatment | Follow-up | ||||
|---|---|---|---|---|---|---|---|
| Items | Before enrolment (weeks) −2 to −1 | End of 2-week treatment (weeks) 3 | End of 4-week treatment (weeks) 5 | End of 6-week treatment (weeks) 7 | End of 6 weeks after the end of the treatment follow-up (weeks) 13 | End of 6 months after the onset time follow-up | |
| Recruitment | X | ||||||
| Enrolment | X | ||||||
| Inclusion criteria | X | ||||||
| Exclusion criteria | X | ||||||
| Basic characteristic variables | X | ||||||
| Randomization and allocation concealment | X | ||||||
| Primary outcomes | Western Aphasia Battery | X | X | X | X | X | X |
| Chinese Functional Communication Profile | X | X | X | X | X | X | |
| Secondary outcomes | X | X | X | X | X | X | |
| National Institute of Health Stroke Scale | X | X | X | X | X | X | |
| Stroke and Aphasia Quality of Life Scale-39 | X | X | X | X | X | X | |
| Stroke Specific Quality of Life Scale | X | X | X | X | X | X | |
| Health Scale of Traditional Chinese Medicine | X | X | X | X | X | X | |
| Adverse events recorded | X | X | X | ||||
| Relapse | X | X | |||||
| Self-reported drug therapy | X | X | X | X | X | ||
| Compliance | X | X | X | ||||